SCHEMBL902327

SCHEMBL902327

CC(C)OC(=O)c1nc2ccnn2c(O)c1Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PYGL P06737 1/20 0.35
PYGM P11217 1/20 0.35
CCR2 P41597 1/20 0.35
CCR5 P51681 1/20 0.35
RNASEH1 O60930 1/20 0.35
SLC6A2 P23975 1/20 0.34
SLC6A3 Q01959 1/20 0.34
PDE4B Q07343 6/20 0.34
PDE4D Q08499 6/20 0.34
PDE4A P27815 5/20 0.34
PDE4C Q08493 4/20 0.34
GPR139 Q6DWJ6 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
TSHR P16473 1/20 0.32
ALDH1A1 P00352 1/20 0.32
KDM5A P29375 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
KDM5B Q9UGL1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902372 0.91 PDE4D (0.41) PDE4BPDE4DPDE4APDE4CGPR139
SCHEMBL902247 0.91 PDE4B (0.40) PDE4BPDE4DPDE4APDE4CNPSR1
SCHEMBL902478 0.89 TSHR (0.39) RNASEH1PDE4BPDE4DPDE4APDE4C
SCHEMBL901817 0.87 KCNN3 (0.41) PYGLPYGMCCR2CCR5PDE4B
SCHEMBL902329 0.87 PDE4A (0.47) RNASEH1PDE4ANPSR1TSHRALDH1A1
SCHEMBL901506 0.85 RNASEH1 (0.38) CCR2CCR5RNASEH1PDE4BPDE4D
SCHEMBL902587 0.84 RNASEH1 (0.46) CCR2CCR5RNASEH1PDE4BPDE4D
SCHEMBL15274731 0.84 KCNN3 (0.41) PDE4ANPSR1TSHRALDH1A1
SCHEMBL901794 0.83 RNASEH1 (0.37) CCR2CCR5RNASEH1PDE4BPDE4D
SCHEMBL902606 0.82 SLC6A3 (0.35) CCR2RNASEH1SLC6A2SLC6A3PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 PYGL 4609/4885PYGM 4640/4885CCR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.